A Phase 1/2 Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma

Trial Profile

A Phase 1/2 Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs IMO 2125 (Primary) ; Ipilimumab (Primary) ; Pembrolizumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Idera Pharmaceuticals
  • Most Recent Events

    • 19 Sep 2017 Planned number of patients changed from 90 to 100.
    • 12 Sep 2017 Results of dose-escalation part (n=18; IMO-2125 + Ipilimumab), presented at the 42nd European Society for Medical Oncology Congress.
    • 10 Sep 2017 Final results from the dose-selection phase of this trial (n = 18) presented in an Idera Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top